The Clinical Influence of the CONUT Score on Survival of Patients With Gastric Cancer Receiving Curative Treatment
The Clinical Influence of the CONUT Score on Survival of Patients With Gastric Cancer Receiving Curative Treatment
复制标题
DOI：
10.21873/invivo.12784
复制
发表时间：
2022-03-01
期刊：
影响因子：
2.3
通讯作者：
Oshima, Takashi
中科院分区：
文献类型：
--
作者：
Aoyama, Toru;Komori, Keisuke;Oshima, Takashi
背景：我们研究了胃癌根治性治疗后，化疗对患者生存和复发的影响。患者和方法：这项研究包括331名在2013年至2017年期间接受根治性手术后接受胃癌辅助治疗的患者。确定了总生存期（OS）和无复发生存期（RFS）的危险因素。结果：根据1、3、5年生存率，CONUT评分2分为最佳分型分界值。低CONUT组的3年和5年OS率分别为93.6%和88.6%，高CONUT组分别为82.7%和73.6%（p=0.022）。低CONUT组的3年和5年RFS率分别为78.8%和68.7%，高CONUT组分别为89.3%和86.6%（p=0.05）。多因素分析显示CONUT评分是OS和RFS的独立预测因素。结论：CONUT评分是胃癌根治术后患者生存的预测因素。根据CONUT评分制定有效的围手术期护理计划和手术策略是必要的。
Background: We investigated the influence of the on survival and recurrence of gastric cancer in patients after curative treatment. Patients and Methods: This study included 331 patients who underwent curative surgery followed by adjuvant treatment for gastric cancer between 2013 and 2017. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. Results: Based on the 1-, 3- and 5-year survival rates, a CONUT score of 2 was regarded as the optimal cut-off value for classification. The 3- and 5-year OS rates were 93.6% and 88.6%, respectively in the low-CONUT group, and 82.7% and 73.6% in high-CONUT group (p=0.022). The 3- and 5year RFS rates were 78.8% and 68.7%, respectively, in the low-CONUT group, and 89.3% and 86.6%, respectively, in the high-CONUT group (p=0.05). A multivariate analysis showed that the CONUT score was a significant independent predictive factor for OS and RFS. Conclusion: The CONUT score was a predictive factor for survival in patients who underwent curative treatment for gastric cancer. It is necessary to develop an effective plan for perioperative care and surgical strategy according to the CONUT score.